Drug-Induced Neutropenia and Agranulocytosis
Drug-induced neutropenia and agranulocytosis are serious and potentially life-threatening complications of pharmacotherapy. The aim of the review was to systematise and analyse scientific literature on the prevalence, risk factors, pathogenesis, clinical picture, methods of prevention and treatment...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation
2020-09-01
|
Series: | Безопасность и риск фармакотерапии |
Subjects: | |
Online Access: | https://www.risksafety.ru/jour/article/view/190 |
id |
doaj-6dabad8bb15945659a9c4665dcc66076 |
---|---|
record_format |
Article |
spelling |
doaj-6dabad8bb15945659a9c4665dcc660762021-07-28T14:03:06ZrusFederal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation Безопасность и риск фармакотерапии2312-78212619-11642020-09-018310912210.30895/2312-7821-2020-8-3-109-122166Drug-Induced Neutropenia and AgranulocytosisO. D. Ostroumova0A. I. Kochetkov1E. E. Pavleeva2E. V. Kravchenko3Russian Medical Academy of Continuous Professional Education; I. M. Sechenov First Moscow State Medical UniversityRussian Medical Academy of Continuous Professional EducationA. I. Yevdokimov Moscow State University of Medicine and DentistryA. I. Yevdokimov Moscow State University of Medicine and DentistryDrug-induced neutropenia and agranulocytosis are serious and potentially life-threatening complications of pharmacotherapy. The aim of the review was to systematise and analyse scientific literature on the prevalence, risk factors, pathogenesis, clinical picture, methods of prevention and treatment of drug-induced neutropenia and agranulocytosis, and medicinal products that most often lead to their development. The analysis revealed that one of the major reasons of drug-induced neutropenia and agranulocytosis is the use of cytotoxic drugs (alkylating agents, antimetabolites, taxanes), non-steroidal anti-inflammatory drugs, antibiotics, antiplatelet, antithyroid, antirheumatic, antiarrhythmic, and antipsychotic drugs. The incidence of drug-induced neutropenia and agranulocytosis is generally low—from 3 to 16 cases per 1 million patients annually. The main risk factors for the development of these conditions include old age, female sex, history of chemotherapy or radiation therapy, malnutrition, and comorbidities. The symptoms in patients with neutropenia and agranulocytosis regardless of etiology can include fever, chills, apathy, myalgia, weakness, pharyngitis, gingivitis, sinusitis, stomatitis, bronchitis, and sepsis. There are no practical methods for early diagnosis or prevention of drug-induced neutropenia and agranulocytosis. Successful management of these conditions relies on timely identification and immediate withdrawal of the potential causative drug. Prevention of chemotherapy-associated neutropenia may consist in reducing the dose of the chemotherapeutic agent. Practicing physicians should be aware of the risk of drug-induced neutropenia and agranulocytosis. It is important to raise awareness among healthcare professionals of the methods of diagnosis and prevention of these conditions, as well as specific aspects of managing patients with these conditions.https://www.risksafety.ru/jour/article/view/190agranulocytosisneutropeniadrugsadverse drug reactions |
collection |
DOAJ |
language |
Russian |
format |
Article |
sources |
DOAJ |
author |
O. D. Ostroumova A. I. Kochetkov E. E. Pavleeva E. V. Kravchenko |
spellingShingle |
O. D. Ostroumova A. I. Kochetkov E. E. Pavleeva E. V. Kravchenko Drug-Induced Neutropenia and Agranulocytosis Безопасность и риск фармакотерапии agranulocytosis neutropenia drugs adverse drug reactions |
author_facet |
O. D. Ostroumova A. I. Kochetkov E. E. Pavleeva E. V. Kravchenko |
author_sort |
O. D. Ostroumova |
title |
Drug-Induced Neutropenia and Agranulocytosis |
title_short |
Drug-Induced Neutropenia and Agranulocytosis |
title_full |
Drug-Induced Neutropenia and Agranulocytosis |
title_fullStr |
Drug-Induced Neutropenia and Agranulocytosis |
title_full_unstemmed |
Drug-Induced Neutropenia and Agranulocytosis |
title_sort |
drug-induced neutropenia and agranulocytosis |
publisher |
Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation |
series |
Безопасность и риск фармакотерапии |
issn |
2312-7821 2619-1164 |
publishDate |
2020-09-01 |
description |
Drug-induced neutropenia and agranulocytosis are serious and potentially life-threatening complications of pharmacotherapy. The aim of the review was to systematise and analyse scientific literature on the prevalence, risk factors, pathogenesis, clinical picture, methods of prevention and treatment of drug-induced neutropenia and agranulocytosis, and medicinal products that most often lead to their development. The analysis revealed that one of the major reasons of drug-induced neutropenia and agranulocytosis is the use of cytotoxic drugs (alkylating agents, antimetabolites, taxanes), non-steroidal anti-inflammatory drugs, antibiotics, antiplatelet, antithyroid, antirheumatic, antiarrhythmic, and antipsychotic drugs. The incidence of drug-induced neutropenia and agranulocytosis is generally low—from 3 to 16 cases per 1 million patients annually. The main risk factors for the development of these conditions include old age, female sex, history of chemotherapy or radiation therapy, malnutrition, and comorbidities. The symptoms in patients with neutropenia and agranulocytosis regardless of etiology can include fever, chills, apathy, myalgia, weakness, pharyngitis, gingivitis, sinusitis, stomatitis, bronchitis, and sepsis. There are no practical methods for early diagnosis or prevention of drug-induced neutropenia and agranulocytosis. Successful management of these conditions relies on timely identification and immediate withdrawal of the potential causative drug. Prevention of chemotherapy-associated neutropenia may consist in reducing the dose of the chemotherapeutic agent. Practicing physicians should be aware of the risk of drug-induced neutropenia and agranulocytosis. It is important to raise awareness among healthcare professionals of the methods of diagnosis and prevention of these conditions, as well as specific aspects of managing patients with these conditions. |
topic |
agranulocytosis neutropenia drugs adverse drug reactions |
url |
https://www.risksafety.ru/jour/article/view/190 |
work_keys_str_mv |
AT odostroumova druginducedneutropeniaandagranulocytosis AT aikochetkov druginducedneutropeniaandagranulocytosis AT eepavleeva druginducedneutropeniaandagranulocytosis AT evkravchenko druginducedneutropeniaandagranulocytosis |
_version_ |
1721268701658873856 |